Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with 99mTc-DTPA-glipizide

Annals of Nuclear Medicine

Volumn 26, Issue 3, 2012, Pages 253-261

  Oh, Chang Sok ^a   Kohanim, Saady ^a   Kong, Fan Lin ^a   Song, Ho Chun ^b   Huynh, Nathan ^a   Mendez, Richard ^a   Chanda, Mithu ^a   Edmund Kim, E ^a   Yang, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Chonnam National University   (South Korea)

Author keywords

99mTc DTPA glipizide; Imaging; Pancreas; Sulfonylurea receptor

Indexed keywords

DIETHYLENEAMINEPENTAACETIC ACID TC 99M GLIPIZIDE CONJUGATE; GLIPIZIDE; GLUCOSE; PENTETATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; STREPTOZOCIN; SULFONYLUREA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR IMAGING; MOLECULAR RECOGNITION; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS TUMOR; PANCREATITIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOCHEMISTRY; RAT; SCINTILLATION CAMERA; THIN LAYER CHROMATOGRAPHY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD GLUCOSE; CELL SIZE; CHELATING AGENTS; FEMALE; GLIPIZIDE; INSULIN-SECRETING CELLS; MOLECULAR IMAGING; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RADIOCHEMISTRY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; TECHNETIUM TC 99M PENTETATE;

EID: 84862687004     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0569-9     Document Type: Article

References (30)

1. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14(10):619-33.
2. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005; 48(11):2221-8.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102-10.
4. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2004;53(1): 250-64.
5. Dwarakanathan A. Diabetes update. J Insur Med. 2006;38(1): 20-30.
6. Robertson C, Drexler AJ, Vernillo AT. Update on diabetes diagnosis and management. J Am Dent Assoc. 2003;134 Spec No:16S-23S.
7. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Investig. 1988;81(2):435-41.
8. Kargar C, Ktorza A. Anatomical versus functional beta-cell mass in experimental diabetes. Diabetes Obes Metab. 2008;10(Suppl 4):43-53.
9. Singhal T, Ding YS, Weinzimmer D, Normandin MD, Labaree D, Ropchan J, et al. Pancreatic beta cell mass PET imaging and quantification with [(11)C]DTBZ and [(18)F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol. 2011;13(5): 973-84.
10. Aguilar-Bryan L, Clement JPt, Gonzalez G, Kunjilwar K, Babenko A, Bryan J. Toward understanding the assembly and structure of KATP channels. Physiol Rev. 1998;78(1):227-45.
11. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3): S368-76.
12. Schwanstecher M, Schwanstecher C, Dickel C, Chudziak F, Moshiri A, Panten U. Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane. Br J Pharmacol. 1994;113(3):903-11.
13. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33(6):1224-9.
14. Schneider S, Feilen PJ, Schreckenberger M, Schwanstecher M, Schwanstecher C, Buchholz HG, et al. In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes. 2005; 113(7):388-95.
15. Schmitz A, Shiue CY, Feng Q, Shiue GG, Deng S, Pourdehnad MT, et al. Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents. Nucl Med Biol. 2004; 31(4):483-91.
16. Schneider S, Ueberberg S, Korobeynikov A, Schechinger W, Schwanstecher C, Schwanstecher M, et al. Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul Pept. 2007;139(1-3):122-7.
17. Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res. 2011;2011:376509.
18. Kitabchi AE, Kaminska E, Fisher JN, Sherman A, Pitts K, Bush A, et al. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci. 2000;319(3):143-8.
19. Prendergast BD. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm. 1984;3(5): 473-85.
20. Assadi M, Eftekhari M, Hozhabrosadati M, Saghari M, Ebrahimi A, Nabipour I, et al. Comparison of methods for determination of glomerular filtration rate: low and high-dose Tc-99m-DTPA renography, predicted creatinine clearance method, and plasma sample method. Int Urol Nephrol. 2008;40(4):1059-65.
21. Hui YH, Huang NH, Ebbert L, Bina H, Chiang A, Maples C, et al. Pharmacokinetic comparisons of tail-bleeding with cannulaor retro-orbital bleeding techniques in rats using six marketed drugs. J Pharmacol Toxicol Methods. 2007;56(2):256-64.
22. Wangler B, Beck C, Shiue CY, Schneider S, Schwanstecher C, Schwanstecher M, et al. Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl- 1-(2-piperidine-1-yl-phenyl)- butyl-carbam oyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent. Bioorg Med Chem Lett. 2004; 14(20):5205-9.
23. Wangler B, Schneider S, Thews O, Schirrmacher E, Comagic S, Feilen P, et al. Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)- 4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]- methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET). Nucl Med Biol. 2004;31(5):639-47.
24. Mishra AK, Hazari PP, Shukla G, Goel V, Chuttani K, Kumar N, et al. Synthesis of specific SPECT-radiopharmaceutical for tumor imaging based on methionine: (99m)Tc-DTPA-bis(methionine). Bioconjug Chem. 2010;21(2):229-39.
25. Mishra AK, Kakkar D, Tiwari AK, Chuttani K, Kaul A, Singh H. Comparative evaluation of glutamate-sensitive radiopharmaceuticals: technetium-99m-glutamic acid and technetium-99mdiethylenetriaminepentaacetic acid-bis(glutamate) conjugate for tumor imaging. Cancer Biother Radiopharm. 2010;25(6):645-55.
26. Hossain GA, Moinul Islam SM, Mahmood S, Khan N, Chakrabarty RK. Tc-99m DTPA scintigraphy in soft tissue tumor. Mymensingh Med J. 2005;14(2):185-8.
27. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol. 2006;33(7):855-64.
28. Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T, Bakal R, Salman M, Davies K, Melman A. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol. 2004;287(4):H1544-53.
29. Goldstein R, Meyer T. Role of everolimus in pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther. 2011;11(11): 1653-65.
30. Snigur GL, Pisarev VB, Spasov AA, Samokhina MP, Bulanov AE. Mechanisms of toxic effect of streptozotocin on beta-cells in the islets of Langerhans. Bull Exp Biol Med. 2009;148(6):937-9.